Register Login

Summit Plc (SMMT)

(10% Negative) Summit Plc (SMMT) Announces Delay in applications Trials for marketing approvals Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 30, 2026, 8:15 a.m.

    📋 Summit Plc (SMMT) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 07:43:04

    Event Type: Clinical Trial Update

    Event Details:

    Summit Plc (SMMT) Announces Clinical Trial Update Summit Plc (SMMT) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: applications
    • Diseases/Conditions: marketing approvals
    • Clinical Stage: clinical trial
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: Akeso Inc.
      • Targeting PD-1 may lead to better efficacy profile1 7 to 10-day half-life could potentially lead to a favorable safety profile.2-4 Dual Blockade of PD-1 & VEGF1 Increased Avidity in TME Presence of VEGF-A efficiently enhances the binding affinity to PD-1 by several fold1 (in vitro) Enhanced Activity of T Cells VEGF dimer leads to potential interconnection of ivonescimab molecules which may increase activity of T cells1 (in vitro) Abbreviations: PD-1=programmed cell death protein 1; TME=tumor microenvironment; VEGF=vascular endothelial growth factor 1. Zhong T, et al. iScience. 2024

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Summit Plc
    • Ticker Symbol: SMMT

Search

News categories